| abstract |
The present invention provides a method for inhibiting the activity of hepatitis C virus (HCV) non-genotype 1 NS3-NS4A protease activity. An amount of VX-950 (a competitively reversible peptide mimic NS3 / 4A protease inhibitor) or a pharmaceutically acceptable salt thereof, and an immunomodulator effective to inhibit the activity of the protease. A method of administering to a patient an additional agent selected from: a cytochrome p45 inhibitor, an antiviral agent, a second inhibitor of HCV protease, an inhibitor of other targets in the HCV life cycle, or a combination thereof. [Selection figure] None |